156 related articles for article (PubMed ID: 16511516)
61. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
[TBL] [Abstract][Full Text] [Related]
62. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
Stangl S; Wortmann A; Guertler U; Multhoff G
J Immunol; 2006 May; 176(10):6270-6. PubMed ID: 16670338
[TBL] [Abstract][Full Text] [Related]
63. NK cells are intrinsically functional in pigs with Severe Combined Immunodeficiency (SCID) caused by spontaneous mutations in the Artemis gene.
Powell EJ; Cunnick JE; Knetter SM; Loving CL; Waide EH; Dekkers JC; Tuggle CK
Vet Immunol Immunopathol; 2016 Jul; 175():1-6. PubMed ID: 27269786
[TBL] [Abstract][Full Text] [Related]
64. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.
Miller JS; Rooney CM; Curtsinger J; McElmurry R; McCullar V; Verneris MR; Lapteva N; McKenna D; Wagner JE; Blazar BR; Tolar J
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1252-7. PubMed ID: 24816582
[TBL] [Abstract][Full Text] [Related]
65. Cytotoxicity of activated natural killer cells against pediatric solid tumors.
Cho D; Shook DR; Shimasaki N; Chang YH; Fujisaki H; Campana D
Clin Cancer Res; 2010 Aug; 16(15):3901-9. PubMed ID: 20542985
[TBL] [Abstract][Full Text] [Related]
66. In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige//nude and wild-type hosts on C57BL background.
Kärre K; Klein GO; Kiessling R; Klein G; Roder JC
Int J Cancer; 1980 Dec; 26(6):789-97. PubMed ID: 7216547
[TBL] [Abstract][Full Text] [Related]
67. Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies.
Tanaka J; Miller JS
Blood Rev; 2020 Nov; 44():100678. PubMed ID: 32229065
[TBL] [Abstract][Full Text] [Related]
68. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
69. Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study.
Holubova M; Miklikova M; Leba M; Georgiev D; Jindra P; Caprnda M; Ciccocioppo R; Kruzliak P; Lysak D
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2561-2567. PubMed ID: 27614454
[TBL] [Abstract][Full Text] [Related]
70. Natural killer cell-mediated immunosurveillance of human cancer.
Malmberg KJ; Carlsten M; Björklund A; Sohlberg E; Bryceson YT; Ljunggren HG
Semin Immunol; 2017 Jun; 31():20-29. PubMed ID: 28888619
[TBL] [Abstract][Full Text] [Related]
71. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.
Verneris MR; Baker J; Edinger M; Negrin RS
J Clin Immunol; 2002 May; 22(3):131-6. PubMed ID: 12078854
[TBL] [Abstract][Full Text] [Related]
72. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
Somanchi SS; Somanchi A; Cooper LJ; Lee DA
Blood; 2012 May; 119(22):5164-72. PubMed ID: 22498742
[TBL] [Abstract][Full Text] [Related]
73. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
Zhao XY; Jiang Q; Jiang H; Hu LJ; Zhao T; Yu XX; Huang XJ
Eur J Immunol; 2020 Sep; 50(9):1374-1385. PubMed ID: 32357256
[TBL] [Abstract][Full Text] [Related]
74. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
[TBL] [Abstract][Full Text] [Related]
75. Noninvasive In Vivo Fluorescence Imaging of NK Cells in Preclinical Models of Adoptive Immunotherapy.
Somanchi SS
Methods Mol Biol; 2016; 1441():307-16. PubMed ID: 27177677
[TBL] [Abstract][Full Text] [Related]
76. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
[TBL] [Abstract][Full Text] [Related]
77. Ex-vivo expansion of NK cells: what is the priority--high yield or high purity?
Berg M; Childs R
Cytotherapy; 2010 Dec; 12(8):969-70. PubMed ID: 21073262
[No Abstract] [Full Text] [Related]
78. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Front Biosci (Landmark Ed); 2017 Jan; 22(2):370-384. PubMed ID: 27814619
[TBL] [Abstract][Full Text] [Related]
79. Measurement of Average Telomere Length in Ex Vivo Expanded Natural Killer Cells by Fluorescence In Situ Hybridization (FISH) and Flow Cytometry.
Maiti SN
Methods Mol Biol; 2016; 1441():57-63. PubMed ID: 27177656
[TBL] [Abstract][Full Text] [Related]
80. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.
Somanchi SS; Lee DA
Methods Mol Biol; 2016; 1441():175-93. PubMed ID: 27177666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
